Nasus Pharma LTD (NSRX) — 6-K Filings

All 6-K filings from Nasus Pharma LTD. Browse 10 Foreign Current Report reports with AI-powered summaries and risk analysis.

6-K Filings (10)

Nasus Pharma Files Routine 6-K Foreign Issuer Report — Mar 25, 2026
Nasus Pharma Ltd. filed a 6-K report on March 25, 2026, indicating a routine foreign issuer report. This filing, with accession number 0001493152-26-012663, inc
6-K Filing — Dec 29, 2025
6-K Filing — Dec 22, 2025
Nasus Pharma Appoints New CFO — Nov 20, 2025 Risk: low
On November 19, 2025, Nasus Pharma Ltd. appointed Eyal Rubin as its new Chief Financial Officer (CFO) and Executive Vice President. The company entered into an
Nasus Pharma Doses First Patient in NS002 Phase 2 Study — Nov 18, 2025 Risk: medium
Nasus Pharma Ltd. announced on November 18, 2025, the initiation of a Phase 2 clinical study for its drug candidate NS002. The first participant has been dosed,
Nasus Pharma Ltd. Updates Corporate Presentation — Nov 3, 2025 Risk: low
On November 3, 2025, Nasus Pharma Ltd. made available an updated corporate presentation on its website. This presentation is attached as Exhibit 99.1 to their F
Nasus Pharma Extends Aptar Collaboration for Epinephrine Program — Oct 8, 2025 Risk: medium
On October 6, 2025, Nasus Pharma Ltd. extended its collaboration with AptarGroup, Inc. to advance the development and commercialization of its intranasal Epinep
Nasus Pharma Ltd. Closes Partial Over-Allotment Option Exercise — Sep 30, 2025 Risk: low
On September 30, 2025, Nasus Pharma Ltd. partially exercised its IPO over-allotment option, selling an additional 3,824 ordinary shares at $8.00 per share. The
Nasus Pharma CEO Joins Board of Directors — Sep 5, 2025 Risk: low
On September 3, 2025, Nasus Pharma Ltd. appointed its CEO, Dan Teleman, to fill a vacancy on its Board of Directors. Mr. Teleman will serve as a Class III direc
Nasus Pharma Closes Initial Public Offering — Aug 14, 2025 Risk: medium
On August 14, 2025, Nasus Pharma Ltd. announced the closing of its Initial Public Offering (IPO). The company, headquartered in Tel Aviv, Israel, filed this rep

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX